and Streptococci: Initial results from a Global Surveillance Program
This study was designed to examine the activity of telavancin against
both enterococci and streptococci pathogens versus the commonly used
drugs vancomycin, levofloxacin, daptomycin, linezolid and
quinupristin/dalfopristin. In the more than 2,700 clinical isolates
tested, telavancin was one of the most potent agents. When evaluated
in light of other data on bactericidal effect in staphylococci
infections, the totality of data suggest clinical activity across the
range of Gram-positive bacteria.
The ATLAS studies were two separate but identical, randomized, double-blind trials to evaluate the efficacy and safety of telavancin versus vancomycin in patients with cSSSIs, especially those due to MRSA. In the ATLAS studies, telavancin contained the largest subset of patients over 18 years old with surgical-site associated cSSSIs of any randomized, double-blind study to date. The most common adverse events reported in patients receiving telavancin were mild to moderate taste disturbance and nausea. In addition, consistent with previous studies, small percentages of telavancin-treated patients experienced renal adverse events or increases in the QTc interval. In ATLAS, the most commonly reported (>10%) adverse events in patients treated with telavancin were taste disturbance, nausea, vomiting, headache, and foamy urine.
MRSA: A Growing Global Epidemic
An estimated 1.2 million hospitalized patients in the United States may
be infected with MRSA, a type of bacteria that is resistant to antibiotics
commonly used to treat staphylococci infections. In the healthcare setting,
the proportion of resistant infections has grown. In 2004, according to the
Centers for Disease Control (CDC), MRSA infections accounted for
|SOURCE Astellas Pharma US, Inc.|
Copyright©2007 PR Newswire.
All rights reserved